ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMGastos comerciales, generales y administrativos135.4 M135.7 M138.7 M138.9 M124.3 M135.8 M537.7 MInvestigación y desarrollo32.9 M27.5 M25.6 M28.2 M25.5 M27.1 M106.4 MBeneficio operativo-39.1 M-29 M-329.2 M-23.3 M-5.7 M-30.7 M-388.9 MTotal de ingresos no operativos-100 K-400 K-1.4 M-2.9 M-3.2 M-3.4 M-10.9 MGastos por intereses, netos de intereses capitalizados700 K800 K1.5 M3.8 M4.4 M4.1 M13.8 MIngresos no operativos, una vez deducidos los gastos por intereses-400 K-500 K-2.8 M-7.1 M-8 M-7.5 M-25.4 MIngresos/gastos extraordinarios300 K100 K-100 K400 K400 K0700 KBeneficio antes de impuestos-39.2 M-29.4 M-330.6 M-26.2 M-8.9 M-34.1 M-399.8 MParticipación en los beneficios———————Impuestos3.3 M-29.3 M-100 K1.2 M-1 M0100 KParticipación minoritaria———————Otros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas-42.5 M-100 K-330.5 M-27.4 M-7.9 M-34.1 M-399.9 MOperaciones suspendidas———————Beneficio neto-42.5 M-100 K-330.5 M-27.4 M-7.9 M-34.1 M-399.9 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas-42.5 M-100 K-330.5 M-27.4 M-7.9 M-34.1 M-399.9 MBeneficio básico por acción-0.470-3.57-0.29-0.09-0.36-4.31Beneficio por acción diluido-0.470-3.57-0.29-0.09-0.36-4.31Número medio de acciones ordinarias90.6 M91.4 M92.5 M93.1 M92.6 M93.7 M—Acciones diluidas90.6 M91.4 M92.5 M93.1 M92.6 M93.7 M—EBITDA8.3 M-14.5 M-314.9 M-10.6 M33.7 M-18.1 M-309.9 MEBIT-39.1 M-29 M-329.2 M-23.3 M-5.7 M-30.7 M-388.9 MCosto de los ingresos59.7 M61.7 M61.3 M61.9 M63 M62.8 M249 MOtros costes de producción———————Amortización y depreciación (flujo de caja)47.3 M14.5 M14.3 M12.7 M39.4 M12.6 M79 M
Myriad Genetics, Inc. - Common Stock
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity.